Tokyo, Sept 12, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into a partnership agreement to supply the Sabin Vaccine Institute (Headquarters: Washington D.C., President: Dr. Peter Hotez, “Sabin”) with E6020, an in-house developed adjuvant that enhances the immune effects of vaccines, as well as all relevant information pertaining to the compound free of charge, to support the development of vaccines for two neglected tropical diseases (NTDs) - Chagas disease and leishmaniasis. E6020 stimulates the body’s immune system via TLR4 (Toll-like receptor 4), a receptor that plays a key role in the body’s innate immune system., and is expected to be used in a broad range of antigen vaccines to enhance vaccine efficacy.
